Trientine Hydrochloride
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06824 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | thyroid gland undifferentiated (anaplastic) carcinoma | KG + DL |
| 2 | idiopathic copper-associated cirrhosis | KG + DL |
| 3 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 4 | hepatoportal sclerosis | KG + DL |
| 5 | primitive portal vein thrombosis | KG + DL |
| 6 | hepatopulmonary syndrome | KG + DL |
| 7 | hepatic porphyria | KG + DL |
| 8 | disorder of tyrosine metabolism | KG + DL |
| 9 | unclassified renal cell carcinoma | KG + DL |
| 10 | renal cell carcinoma associated with neuroblastoma | KG + DL |
| 11 | renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions | KG + DL |
| 12 | tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria | KG + DL |
| 13 | Carney complex | KG + DL |
| 14 | myxoma | KG + DL |
| 15 | angiomyxoma | KG + DL |
| 16 | peripheral dysostosis | KG + DL |
| 17 | teratogenic Pierre Robin syndrome | KG + DL |
| 18 | renal carcinoma | KG + DL |
| 19 | childhood kidney cell carcinoma | KG + DL |
| 20 | botryoid-type embryonal rhabdomyosarcoma of the vagina | KG + DL |
| 21 | parameningeal embryonal rhabdomyosarcoma | KG + DL |
| 22 | angiolipoma | KG + DL |
| 23 | nasopharyngeal squamous cell carcinoma | KG + DL |
| 24 | familial spontaneous pneumothorax | KG + DL |
| 25 | disorder of phenylalanine metabolism | KG + DL |
| 26 | embryonal extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 27 | collecting duct carcinoma | KG + DL |
| 28 | nodular regenerative hyperplasia of the liver | KG + DL |
| 29 | prostate embryonal rhabdomyosarcoma | KG + DL |
| 30 | endocrine-cerebro-osteodysplasia syndrome | KG + DL |
| 31 | triple-negative breast carcinoma | KG + DL |
| 32 | cecal neoplasm | KG + DL |
| 33 | cecum cancer | KG + DL |
| 34 | Toriello-Lacassie-Droste syndrome | KG + DL |
| 35 | nasopharyngeal carcinoma | KG + DL |
| 36 | extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 37 | liver sarcoma | KG + DL |
| 38 | nasopharyngeal carcinoma, susceptibility to | KG + DL |
| 39 | rhabdomyosarcoma (disease) | KG + DL |
| 40 | diabetic neuropathy | KG + DL |
| 41 | renal pelvis carcinoma | KG + DL |
| 42 | sarcomatoid renal cell carcinoma | KG + DL |
| 43 | acrodysostosis with or without hormone resistance | KG + DL |
| 44 | chromophobe renal cell carcinoma | KG + DL |
| 45 | thyroid adenoma (disease) | KG + DL |
| 46 | familial colorectal cancer | KG + DL |
| 47 | pleural adenomatoid tumor | KG + DL |
| 48 | papillary craniopharyngioma | KG + DL |
| 49 | glycogen storage disease due to lactate dehydrogenase H-subunit deficiency | KG + DL |
| 50 | pleural mesothelioma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.